Login / Signup

Salvianolic acid B noncovalently interacts with disordered c-Myc: a computational and spectroscopic-based study.

Ashutosh SinghAnkur KumarRajanish GiriTaniya BhardwajRajanish GiriNeha Garg
Published in: Future medicinal chemistry (2021)
Aims: c-Myc, along with its partner MAX, regulates the expression of several genes, leading to an oncogenic phenotype. The MAX interacting interface of c-Myc is disordered and uncharacterized for small molecule binding. Salvianolic acid B possesses numerous therapeutic properties, including anticancer activity. The current study was designed to elucidate the interaction of the Sal_Ac_B with the disordered bHLH domain of c-Myc using computational and biophysical techniques. Materials & methods: The binding of Sal_Ac_B with Myc was studied using computational and biophysical techniques, including molecular docking and simulation, fluorescence lifetime, circular dichroism and anisotropy. Results & conclusions: The study demonstrated a high binding potential of Sal_Ac_B against the disordered Myc peptide. The binding of the compounds leads to an overall conformational change in Myc. Moreover, an extensive simulation study showed a stable Sal_Ac_B/Myc binding.
Keyphrases
  • molecular docking
  • transcription factor
  • binding protein
  • dna binding
  • small molecule
  • poor prognosis
  • risk assessment
  • gene expression
  • hepatitis c virus
  • hiv infected
  • human health